Lofton notes the investigational drug hits three hormone receptors, where current medications target only one or two incretin pathways.
Recap by typeshit. Post by @drhollylofton on Instagram.
He says close to 40% of weight lost in the trial's body-scan group was lean mass, and argues muscle loss isn't the drug's fault.
Wayne Pratt walks through what happens in the brain when drugs like Ozempic dial down the constant background chatter about eating.
Bikman cites a trial where people who lost about 21% and switched to placebo regained 14% within a year, while those who stayed on kept losing.
In Genome Medicine, diet-triggered delivery beat constant secretion on fat and liver fat, and kept down gut microbes carrying GLP-1-degrading peptidase genes.
The interim policy, reported by AP, would shield some pharmacies from enforcement over restricted peptides. FDA had flagged risks like contamination and tumor growth.
A propensity-matched analysis looks at whether GLP-1 receptor agonist use tracks with cancer incidence and overall survival in bladder and renal cell carcinoma.
Loading…